In this article, we deep dive into the 5 stocks delivering huge gains. For a deeper discussion and an extended list, please see 9 Stocks Crushing the Market With Surging Returns.
The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels
5. Redwire Corp. (NYSE:RDW)
Redwire finished Thursday’s trading session sweet, soaring 15.09 percent to close at $21.43 after bagging a contract to grow strawberries in space.
In a statement, Redwire Corp. (NYSE:RDW) said that it was awarded by Astrobiome Space—a Luxembourg-based biotech company pioneering microbiome solutions for regenerative space agriculture—to grow strawberries and test proprietary soil enhancement product inside the Redwire Greenhouse systems while on board the International Space Station.
The test crops are expected to begin this month in preparation for the ISS flight.
Astrobiome Space’s biostimulant—developed from microbes adapted to the extreme space environments—will be used to grow the first wild strawberries ever cultivated in orbit. The product is expected to enhance the fruit’s natural resilience and nutrient density, including higher levels of vitamin C, potassium, flavonoids, polyphenols, and antioxidants, bringing orbital crops closer to the quality of wild-grown produce on Earth.
“With our Greenhouse platform, we are not only enabling fundamental research, but we are also demonstrating the practical cultivation of fresh food in space—including crops such as strawberries and fungi. These capabilities are essential as we prepare for long-duration missions and future habitats, while also generating valuable insights to improve agricultural practices here on Earth,” said Marc Dielissen, executive vice president for Redwire Corp.’s (NYSE:RDW) European operations.
The said contract marks the inaugural flight for Redwire Corp.’s (NYSE:RDW) trailblazing Greenhouse system—the world’s first commercial space greenhouse.
“The Redwire Greenhouse provides a simple, scalable commercial solution for customers seeking to advance crop science from benchtop laboratory facilities to true production in space. Along with supporting long-term NASA exploration plans, the Redwire Greenhouse will also provide unprecedented research opportunities for institutional and commercial customers with various plant science and industrial research goals,” Redwire Corp. (NYSE:RDW) said.
4. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Iovance Biotherapeutics climbed by 15.57 percent on Thursday to end at $4.38 apiece after securing the conditional approval of Australia’s Therapeutic Goods Administration (TGA) for the treatment of melanoma through its therapy, Amtagvi.
The approval marked Iovance Biotherapeutics Inc.’s (NASDAQ:IOVA) third marketing authorization for Amtagvi, after earlier securing the approval of the US and Canada.
The company posted an optimistic outlook about Amtagvi’s business prospects in Australia, with the country having the highest rate of melanoma globally, with an estimated 17,000 new cases diagnosed each year and more than 1,500 deaths annually.
“This approval … marks a significant step forward for Iovance in the country with the highest rate of melanoma globally,” Iovance Biotherapeutics Inc. (NASDAQ:IOVA) President and CEO Frederick Vogt.
“We are in the process of authorizing our first Australian treatment center as we advance our expansion strategy for Amtagvi in additional markets with a high prevalence of advanced melanoma.”
TGA granted approval based on safety and efficacy results from the global, multicenter C-144-01 trial investigating Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 therapy and targeted therapy, if applicable.
3. Abivax SA (NASDAQ:ABVX)
Abivax soared by 16.39 percent on Thursday to close at $104.93 apiece as investors continued to hunt for bargains following the previous days’ lows, dragged by concerns about its cancer therapy candidate.
Earlier in the week, Abivax SA (NASDAQ:ABVX) announced strong clinical trial results from the third phase study evaluating Obefazimod in patients with moderate to severe active ulcerative colitis.
While the drug achieved its primary endpoint of demonstrating clinically meaningful efficacy and a placebo-adjusted remission rate of about 40 percent, the results were overshadowed by concerns about other cancer cases taking higher doses.
″[The] cancer signal complicates matters,” said investment firm Jefferies in its market note.
“Even if unrelated noise, we think the overhang will be real, especially considering the absence of other value-inflecting data events over the next [year].”
Following the results, Jefferies downgraded Abivax SA (NASDAQ:ABVX) to hold from buy, as well as its price target, by 43.75 percent to $90 from $160 previously.
Apart from Jefferies, Abivax SA (NASDAQ:ABVX) also earned a 22-percent lower price target from Wolfe Research, to $136 from $176 previously, but maintained its outperform rating for its stock.
Wolfe said that the coverage was based on various factors, including background rates higher than normal, an older patient population, and the lack of a data safety monitoring board and nonclinical genotoxicity signals.
However, the listed firm is set to provide a safety and efficacy update later this month, which Wolfe said may reinforce optimism anew among investors on expectations that the biopharmaceutical firm would devise a communication strategy to address concerns.
2. Innio NV (NASDAQ:INIO)
Innio soared by 23.33 percent in its first day as a publicly-listed company, riding the strong investor optimism for energy stocks amid the continued growing demand.
In intra-day trading, Innio NV (NASDAQ:INIO) opened at $31, marking a jump of 14.8 percent from its initial public offering price of $27, climbed by as high as 27.6 percent to $34.45, before trimming gains to end the session at $33.30.
Innio NV (NASDAQ:INIO) said that the IPO consisted of 90 million secondary shares, sold for $27 apiece for a total of $2.43 billion, and will be fully received by the selling shareholder. This means that Innio NV (NASDAQ:INIO) will not receive any amount from the proceeds.
Meanwhile, the company also granted its underwriters the right to purchase up to an additional 13.5 million shares from the selling shareholder at the IPO price, for a total of $364.5 million.
Backed by Advent and ADIA, Innio NV (NASDAQ:INIO) is a global distributed energy solutions provider that commits to delivering reliable, flexible, transient, decentralized, modular, and efficient power through the design, manufacture, and service of high-performance power systems under its Jenbacher and Waukesha brands.
The company delivers power for applications including data centers, microgrids, grid stabilization, industrial energy, and gas compression.
1. Liftoff Mobile Inc. (NASDAQ:LFTO)
Shares in Liftoff Mobile took off by 23.70 percent in its first trading day as a listed company, closing at $28.45 apiece, on strong investor optimism for mobile app marketing technology players.
Liftoff Mobile Inc. (NASDAQ:LFTO)—a firm backed by Blackstone—successfully raised $437 million in its initial public offering following the successful sale of 19 million shares at $23 apiece.
Investment funds affiliated with General Atlantic, L.P., have been allocated approximately 1.3 million common shares.
It also granted its underwriters a 30-day option to purchase up to an additional 2.85 million common shares for overallotments at the IPO price, less underwriting discounts and commissions.
Liftoff Mobile Inc. (NASDAQ:LFTO) said that proceeds from the offer will be used to repay $357.3 million of debt under its new term loan facility ending in 2032, while the balance will be used for general corporate purposes.
“The biggest priority is enhancing the company’s machine learning model and improving predictions for better ad recommendations so that we can price them more intelligently,” Liftoff Mobile Inc. (NASDAQ:LFTO) CEO Jeremy Bondy said “That allows us to do more user acquisition and optimize marketing spend for our advertisers.”
Liftoff Mobile Inc. (NASDAQ:LFTO) was set to list in February this year, initially targeting as much as $762 million, but later walked back following a selloff in software stocks over concerns about the impact of artificial intelligence.
While we acknowledge the potential of LFTO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LFTO and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
